EnClear Therapies
EnClear Therapies aims to improve and extend the lives of patients suffering from CNS diseases through precision dosing. They are building an integrated neurotechnology business utilizing their proprietary EnTrega CSF Platform to create patient-focused opportunities, initially launching into neuro-oncology and expanding into neurodegenerative, lysosomal storage, and autoimmune diseases through partnerships.
Industries
Nr. of Employees
small (1-50)
EnClear Therapies
Cambridge, Massachusetts, United States, North America
Patents
Methods of amelioration of cerebrospinal fluid and devices and systems therefor
US-11278657-B2
View Details
Methods of amelioration of cerebrospinal fluid and devices and systems therefor
US-11278657-B2
View DetailsProducts
CSF delivery and monitoring platform (in development)
A platform that provides controlled, continuous, and personalized delivery of therapeutics via CSF combined with monitoring capabilities and integrated ML/AI for dosing optimization; intended to improve CNS distribution and enable outpatient administration.
EnTrega CSF PLATFORM
Localized CNS delivery of therapeutics and monitoring of CSF to ensure effective and personalized therapy.
CSF delivery and monitoring platform (in development)
A platform that provides controlled, continuous, and personalized delivery of therapeutics via CSF combined with monitoring capabilities and integrated ML/AI for dosing optimization; intended to improve CNS distribution and enable outpatient administration.
EnTrega CSF PLATFORM
Localized CNS delivery of therapeutics and monitoring of CSF to ensure effective and personalized therapy.
Services
Collaborative development agreements to apply CSF delivery and monitoring to externally developed therapeutics (small molecules, ASOs, AAVs, siRNAs, enzyme therapies) and to optimize dosing profiles.
Preclinical studies and testing to characterize CNS drug distribution and compare CSF-based delivery to standard intrathecal/intraventricular approaches.
Collaborative development agreements to apply CSF delivery and monitoring to externally developed therapeutics (small molecules, ASOs, AAVs, siRNAs, enzyme therapies) and to optimize dosing profiles.
Preclinical studies and testing to characterize CNS drug distribution and compare CSF-based delivery to standard intrathecal/intraventricular approaches.
Expertise Areas
- CSF-based drug delivery
- Precision dosing and personalized CNS therapeutics
- Neuro-oncology (leptomeningeal carcinomatosis)
- Preclinical CNS pharmacokinetics and biodistribution
Key Technologies
- CSF delivery systems
- Closed-loop control systems
- Machine learning / AI-driven dosing optimization
- Intrathecal and intraventricular infusion techniques
News & Updates
EnClear Therapies showcased at the Emerging Medtech Spotlight.
EnClear Therapies received the 2020 GHP Biotechnology Award.
EnClear Therapies announced a $10 million Series A financing round.
EnClear Therapies showcased at the Emerging Medtech Spotlight.
EnClear Therapies received the 2020 GHP Biotechnology Award.
EnClear Therapies announced a $10 million Series A financing round.